Pharmacological reactivation of autophagic flux by natural compounds or synthetic cell-permeable peptide prevents doxorubicin-induced cardiomyopathy - Quiz - MDSpire

Pharmacological reactivation of autophagic flux by natural compounds or synthetic cell-permeable peptide prevents doxorubicin-induced cardiomyopathy

  • By

  • Leonardo Schirone

  • Daniele Vecchio

  • Valentina Valenti

  • Vittorio Picchio

  • Sonia Schiavon

  • Luca D’Ambrosio

  • Flavio di Nonno

  • Selenia Miglietta

  • Michela Relucenti

  • Luca Madaro

  • Silvia Palmerio

  • Claudia Cozzolino

  • Margherita Litterio

  • Gianmarco Sarto

  • Beatrice Simeone

  • Nicola Moro

  • Shazia Tahir

  • Tania Zaglia

  • Giuseppe Biondi Zoccai

  • Elena De Falco

  • Vincenzo Petrozza

  • Ernesto Greco

  • Giacomo Frati

  • Maurizio Forte

  • Sebastiano Sciarretta

  • March 29, 2026

  • 0 min

Share

Original Source(s)

Pharmacological reactivation of autophagic flux by natural compounds or synthetic cell-permeable peptide prevents doxorubicin-induced cardiomyopathy

  • by Leonardo Schirone, Daniele Vecchio, Valentina Valenti, Vittorio Picchio, Sonia Schiavon, Luca D’Ambrosio, Flavio di Nonno, Selenia Miglietta, Michela Relucenti, Luca Madaro, Silvia Palmerio, Claudia Cozzolino, Margherita Litterio, Gianmarco Sarto, Beatrice Simeone, Nicola Moro, Shazia Tahir, Tania Zaglia, Giuseppe Biondi Zoccai, Elena De Falco, Vincenzo Petrozza, Ernesto Greco, Giacomo Frati, Maurizio Forte, Sebastiano Sciarretta

  • March 29, 2026

Related Content

Case Report: Long-term survival in advanced PD-L1-high squamous cell lung cancer following severe immune-related cardiotoxicity

Breaking the Biomarker Bottlenecks: Part 2

Industry leaders from AstraZeneca, Leica Biosystems, and Danaher share their insights on AI’s power to democratize access to precision medicine

  • February 16, 2026

  • 9 min
Understanding cardiac toxicity and immune responses to thoracic radiation therapy in non-small cell lung cancer – implications for future research